{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:55:52Z","timestamp":1792292152172,"version":"4.4.0"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Brain iron dyshomeostasis plays a critical role in the pathology of multiple central nervous system (CNS) disorders, including neurodegenerative and neuropsychiatric diseases. Iron chelators such as deferoxamine (DFO) and deferiprone (DFP) have demonstrated therapeutic potential in mitigating disease progression in these conditions. However, systemic administration is hindered by poor blood-brain barrier (BBB) permeability, dose-limiting toxicity, and poor patient compliance due to frequent dosing regimens. In recent years, intranasal (IN) drug delivery has emerged as a promising strategy to bypass the BBB, providing a direct nose-to-brain delivery route via olfactory and trigeminal pathways while minimizing systemic exposure. This review provides a comprehensive summary of the current status of iron chelation therapy for CNS disorders with a focus on pharmacokinetics, efficacy, and translational potential of IN administration. While IN DFO has been extensively studied in preclinical models of Alzheimer\u2019s disease and stroke, recent developments have expanded the scope to other chelators such as DFP. We compare traditional systemic routes, including oral and intravenous, with intranasal administration, highlighting their respective advantages and limitations for CNS delivery. With ongoing advances in formulation and delivery technologies, IN iron chelators provide a promising alternative for the treatment of CNS disorders characterized by impaired iron homeostasis in the brain.<\/jats:p>","DOI":"10.3389\/fphar.2025.1709259","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:44:48Z","timestamp":1766040288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Intranasal delivery of iron chelators and management of central nervous system disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruiying","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1021\/acscentsci.9b00284","article-title":"Design of safe nanotherapeutics for the excretion of excess systemic toxic iron","volume":"5","author":"Abbina","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/antiox14050527","article-title":"Ferroptosis and iron homeostasis: molecular mechanisms and neurodegenerative disease implications","volume":"14","author":"Abdukarimov","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/17425247.2018.1471058","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region","volume":"15","author":"Agrawal","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12640-020-00193-1","article-title":"Major depression in children with transfusion-dependent thalassemia is strongly associated with the combined effects of blood transfusion rate, iron overload, and increased pro-inflammatory cytokines","volume":"38","author":"Al-Hakeim","year":"2020","journal-title":"Neurotox. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"618411","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in oral drug delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B8","volume-title":"The effect of developmental iron deficiency on gene expression, tet proteins, and Dna hydroxymethylation in the rodent brain","author":"Amanda","year":"2020"},{"key":"B9","article-title":"Brain De-Ironization with nasal spray of iron chelator in treatment of multiple system atrophy, a case trial","volume-title":"2024 international congress","author":"Amoushahi","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4067\/s0716-97602006000100017","article-title":"Iron and glutathione at the crossroad of redox metabolism in neurons","volume":"39","author":"Aracena","year":"2006","journal-title":"Biol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0254794","DOI":"10.1371\/journal.pone.0254794","article-title":"The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells","volume":"16","author":"Bailey","year":"2021","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1210\/en.2012-1435","article-title":"Brain meets body: the blood-brain barrier as an endocrine interface","volume":"153","author":"Banks","year":"2012","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1753-4887.1993.tb03096.x","article-title":"Iron in the brain","volume":"51","author":"Beard","year":"2009","journal-title":"Nutr. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1007\/s13311-022-01300-0","article-title":"ATH434 rescues pre-motor hyposmia in a mouse model of parkinsonism","volume":"19","author":"Beauchamp","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/clpt.1990.60","article-title":"Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity","volume":"47","author":"Bentur","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00002018-199106010-00004","article-title":"Deferoxamine (desferrioxamine). New toxicities for an old drug","volume":"6","author":"Bentur","year":"1991","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcdb.2021.03.022","article-title":"Olfactory modulation of the medial prefrontal cortex circuitry: implications for social cognition","volume":"129","author":"Bhattarai","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume-title":"Topical Applications And The Mucosa","author":"Bitter","year":"2011"},{"key":"B21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4103\/0110-5558.76436","article-title":"Mucoadhesive drug delivery system: an overview","volume":"1","author":"Boddupalli","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/jfb15110329","article-title":"Development of nanocomposite microspheres for nasal administration of deferiprone in neurodegenerative disorders","volume":"15","author":"Boyuklieva","year":"2024","journal-title":"J. Funct. Biomater."},{"key":"B24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphar.2013.00167","article-title":"Regional siderosis: a new challenge for iron chelation therapy","volume":"4","author":"Cabantchik","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrd2368","article-title":"Modelling of the blood-brain barrier in drug discovery and development","volume":"6","author":"Cecchelli","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/21678707.2019.1613977","article-title":"An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload","volume":"7","author":"Ceci","year":"2019","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","article-title":"A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates. Relevance to inhalation toxicology and human health risk assessment","volume":"153","author":"Chamanza","year":"2015","journal-title":"J. Comp. Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1116516","DOI":"10.3389\/fnagi.2023.1116516","article-title":"The impact of iron deposition on the fear circuit of the brain in patients with Parkinson\u2019s disease and anxiety","volume":"15","author":"Chen","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00204-022-03287-1","article-title":"Reversal of genetic brain iron accumulation by N,N'-bis(2-mercaptoethyl)isophthalamide, a lipophilic metal chelator, in mice","volume":"96","author":"Cheng","year":"2022","journal-title":"Arch. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"B31","unstructured":"A study of deferoxamine (DFO) in people with leptomeningeal metastasis\n          \n          \n          2025"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and Alzheimer's Disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-b","article-title":"Intramuscular desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"Crapper McLachlan","year":"1991","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1742-6723.2010.01257.x","article-title":"Does the standard intravenous solution of fentanyl (50 microg\/mL) administered intranasally have analgesic efficacy?","volume":"22","author":"Crellin","year":"2010","journal-title":"Emerg. Med. Australas."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1515\/9783110527872-009","article-title":"Iron chelation for iron overload in thalassemia","volume":"19","author":"Crisponi","year":"2019","journal-title":"Met. Ions Life Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pharmaceutics14030629","article-title":"Evaluation of recent intranasal drug delivery systems to the central nervous system","volume":"14","author":"Crowe","year":"2022","journal-title":"Pharmaceutics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/070674379403900104","article-title":"Iron overload and psychiatric illness","volume":"39","author":"Cutler","year":"1994","journal-title":"Can. J. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.2217\/nnm-2021-0311","article-title":"Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities","volume":"16","author":"D'Souza","year":"2021","journal-title":"Nanomedicine (Lond)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1506944","DOI":"10.3389\/fphar.2024.1506944","article-title":"Progressive iron overload in middle-aged mice impairs olfactory function, triggers lipid oxidation and induces apoptosis","volume":"15","author":"Deng","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of deferiprone in Parkinson's disease","volume":"387","author":"Devos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2105\/AJPH.2008.146647","article-title":"Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose","volume":"99","author":"Doe-Simkins","year":"2009","journal-title":"Am. J. Public Health"},{"key":"B44","year":"2025","journal-title":"Deferoxamine prices, coupons, copay cards and patient assistance"},{"key":"B45","doi-asserted-by":"publisher","first-page":"115343","DOI":"10.1016\/j.bbr.2024.115343","article-title":"Iron metabolism dysfunction in neuropsychiatric disorders: implications for therapeutic intervention","volume":"479","author":"Duarte-Silva","year":"2025","journal-title":"Behav. Brain Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J. Trace Elem. Med. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4911205","DOI":"10.1155\/2022\/4911205","article-title":"Iron chelators in treatment of iron overload","volume":"2022","author":"Entezari","year":"2022","journal-title":"J. Toxicol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/acs.molpharmaceut.0c00474","article-title":"Challenges and opportunities of deferoxamine delivery for treatment of Alzheimer's disease, Parkinson's disease, and intracerebral hemorrhage","volume":"18","author":"Farr","year":"2021","journal-title":"Mol. Pharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.expneurol.2013.03.017","article-title":"Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model","volume":"247","author":"Febbraro","year":"2013","journal-title":"Exp. Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00221-012-3101-0","article-title":"Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1\u03b1, and phosphorylates GSK3\u03b2 in P301L tau transgenic mice","volume":"219","author":"Fine","year":"2012","journal-title":"Exp. Brain Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.brainres.2014.05.048","article-title":"Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson\u05f3s disease","volume":"1574","author":"Fine","year":"2014","journal-title":"Brain Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.neulet.2014.11.013","article-title":"Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP\/PS1 model of amyloid accumulation","volume":"584","author":"Fine","year":"2015","journal-title":"Neurosci. Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jns.2017.07.028","article-title":"Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease","volume":"380","author":"Fine","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1528374","DOI":"10.3389\/fnins.2024.1528374","article-title":"Low-dose intranasal deferoxamine modulates memory, neuroinflammation, and the neuronal transcriptome in the streptozotocin rodent model of Alzheimer's disease","volume":"18","author":"Fine","year":"2024","journal-title":"Front. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jhep.2010.04.039","article-title":"Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation","volume":"53","author":"Finkenstedt","year":"2010","journal-title":"J. Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","author":"Fowler","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0194599811427519","article-title":"Effects of anatomy and particle size on nasal sprays and nebulizers","volume":"146","author":"Frank","year":"2012","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"B200","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0300-483X(88)90010-8","article-title":"Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis","volume":"49","author":"Freedman","year":"1988","journal-title":"Toxicology"},{"key":"B69","first-page":"89","volume-title":"Neurologic agents for nasal administration to the brain","author":"Frey","year":"1991"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMe2213120","article-title":"Lack of benefit of iron chelation in early Parkinson's disease","volume":"387","author":"Galasko","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"Ganger","year":"2018","journal-title":"Pharmaceutics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol."},{"key":"B73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/B978-0-12-823292-7.00017-6","article-title":"Diagnosis and treatment of metal poisoning general aspects","volume-title":"Handbook on the toxicology of metals","author":"Gerhardsson","year":"2022"},{"key":"B74","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.clp.2023.07.009","article-title":"Anemia, Iron supplementation, and the brain","volume":"50","author":"Gisslen","year":"2023","journal-title":"Clin. Perinatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41598-020-58386-9","article-title":"The iron chelator deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability","volume":"10","author":"Gottwald","year":"2020","journal-title":"Sci. Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e43960","DOI":"10.7759\/cureus.43960","article-title":"Epigenetics in neurological and psychiatric disorders: a comprehensive review of current understanding and future perspectives","volume":"15","author":"Grezenko","year":"2023","journal-title":"Cureus"},{"key":"B78","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.neurobiolaging.2012.05.009","article-title":"Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of alzheimer's disease","volume":"34","author":"Guo","year":"","journal-title":"Neurobiol. Aging"},{"key":"B79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neuint.2012.12.005","article-title":"Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain","volume":"62","author":"Guo","year":"","journal-title":"Neurochem. Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fnagi.2015.00104","article-title":"Intranasal deferoxamine attenuates synapse loss via up-regulating the P38\/HIF-1\u03b1 pathway on the brain of APP\/PS1 transgenic mice","volume":"7","author":"Guo","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.expneurol.2016.03.016","article-title":"Deferoxamine-mediated up-regulation of HIF-1\u03b1 prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice","volume":"280","author":"Guo","year":"2016","journal-title":"Exp. Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1016\/j.wneu.2019.05.024","article-title":"Deferoxamine alleviates iron overload and brain injury in a rat model of brainstem hemorrhage","volume":"128","author":"Guo","year":"2019","journal-title":"World Neurosurg."},{"key":"B83","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/jpet.108.149807","article-title":"Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke","volume":"330","author":"Hanson","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s13346-011-0050-2","article-title":"Intranasal delivery of deferoxamine reduces spatial memory loss in APP\/PS1 mice","volume":"2","author":"Hanson","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnagi.2013.00034","article-title":"A delicate balance: iron metabolism and diseases of the brain","volume":"5","author":"Hare","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41398-022-02081-y","article-title":"Olfactory impairment in psychiatric disorders: does nasal inflammation impact disease psychophysiology?","volume":"12","author":"Hasegawa","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/2040620712450252","article-title":"Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia","volume":"3","author":"Jamuar","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.31887\/DCNS.2017.19.2\/cjones","article-title":"Oxytocin and social functioning","volume":"19","author":"Jones","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1185\/03007990802077442","article-title":"Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom","volume":"24","author":"Karnon","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"B90","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jnutbio.2014.07.003","article-title":"Iron and mechanisms of emotional behavior","volume":"25","author":"Kim","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/DDDT.S79458","article-title":"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes","volume":"10","author":"Kontoghiorghes","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"B95","first-page":"371","article-title":"The effects of subcutaneous deferoxamine administration on renal function in thalassemia major","volume":"54","author":"Koren","year":"1991","journal-title":"Int. J. Hematol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph14020095","article-title":"Mechanisms of intranasal deferoxamine in neurodegenerative and neurovascular disease","volume":"14","author":"Kosyakovsky","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1039\/c4mt00164h","article-title":"Iron regulatory proteins and their role in controlling iron metabolism","volume":"7","author":"K\u00fchn","year":"2015","journal-title":"Metallomics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biom12030365","article-title":"Effects of deferasirox in Alzheimer's disease and tauopathy animal models","volume":"12","author":"Kwan","year":"2022","journal-title":"Biomolecules"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1212\/wnl.0000000000205009","article-title":"Projected global burden of brain disorders through 2050 (P7-15.001)","volume":"102","author":"Lei","year":"2024","journal-title":"Neurology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.pmedr.2023.102549","article-title":"Associations of iron deficiency and depressive symptoms among young adult males and females: NHANES 2017 to 2020","volume":"37","author":"Leung","year":"2024","journal-title":"Prev. Med. Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41380-023-02399-z","article-title":"Iron imbalance in neurodegeneration","volume":"29","author":"Levi","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"B103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymeth.2020.06.022","article-title":"Modern epigenetics methods in biological research","volume":"187","author":"Li","year":"2021","journal-title":"Methods"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1177\/0271678X17709186","article-title":"Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice","volume":"37","author":"Li","year":"2017","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"B105","doi-asserted-by":"publisher","first-page":"927334","DOI":"10.3389\/fnmol.2022.927334","article-title":"Iron neurotoxicity and protection by deferoxamine in intracerebral hemorrhage","volume":"15","author":"Li","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fnins.2018.00632","article-title":"Iron and Alzheimer's disease: from pathogenesis to therapeutic implications","volume":"12","author":"Liu","year":"2018","journal-title":"Front. Neurosci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41380-023-01979-3","article-title":"Perturbed iron biology in the prefrontal cortex of people with schizophrenia","volume":"28","author":"Lotan","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"B108","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.physbeh.2008.10.019","article-title":"Impairment of emotional behavior and spatial learning in adult wistar rats by ferrous sulfate","volume":"96","author":"Maaroufi","year":"2009","journal-title":"Physiol. Behav."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3390\/pharmaceutics15082119","article-title":"Optimizing absorption for intranasal delivery of drugs targeting the central nervous system using alkylsaccharide permeation enhancers","volume":"15","author":"Madden","year":"2023","journal-title":"Pharmaceutics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bcmd.2011.07.002","article-title":"Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials","volume":"47","author":"Maggio","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/gerona\/glu314","article-title":"Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging","volume":"71","author":"Maimaiti","year":"2016","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/mds.29145","article-title":"Conservative Iron chelation for neuroferritinopathy","volume":"37","author":"Marchand","year":"2022","journal-title":"Mov. Disord."},{"key":"B114","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jech.29.3.157","article-title":"Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis","volume":"29","author":"Meade","year":"1975","journal-title":"Br. J. Prev. Soc. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/antiox10081270","article-title":"Targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke: safety and optimal dose selection in a randomized clinical trial","volume":"10","author":"Millan","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e31359","DOI":"10.1371\/journal.pone.0031359","article-title":"Visualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia","volume":"7","author":"Miller","year":"2012","journal-title":"PLoS One"},{"key":"B116","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jpsychires.2017.07.006","article-title":"Investigating the relationship between iron and depression","volume":"94","author":"Mills","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10611860903055470","article-title":"Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium","volume":"17","author":"Mistry","year":"2009","journal-title":"J. Drug Target"},{"key":"B118","first-page":"239","article-title":"A review on iron chelators in treatment of iron overload syndromes","volume":"10","author":"Mobarra","year":"2016","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e14607","DOI":"10.1111\/cns.14607","article-title":"Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"30","author":"Negida","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1152\/ajplegacy.1971.221.6.1629","article-title":"Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection","volume":"221","author":"Oldendorf","year":"1971","journal-title":"Am. J. Physiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1056\/NEJMvcm2020745","article-title":"Intranasal naloxone administration","volume":"384","author":"Ortega","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"mfae044","DOI":"10.1093\/mtomcs\/mfae044","article-title":"ATH434, a promising iron-targeting compound for treating iron regulation disorders","volume":"16","author":"Pall","year":"2024","journal-title":"Metallomics"},{"key":"B125","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann. Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRX"},{"key":"B127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","author":"Pardridge","year":"2011","journal-title":"Fluids Barriers CNS"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1015711","DOI":"10.3389\/fmed.2023.1015711","article-title":"Chelating the valley of death: deferoxamine's path from bench to wound clinic","volume":"10","author":"Parker","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B130","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/s0885-3924(02)00522-5","article-title":"Pilot Study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer","volume":"24","author":"Pavis","year":"2002","journal-title":"J. Pain Symptom Manag."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1532-429X-13-45","article-title":"On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure","volume":"13","author":"Pennell","year":"2011","journal-title":"J. Cardiovasc Magn. Reson"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jinorgbio.2011.08.001","article-title":"Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease","volume":"105","author":"Percy","year":"2011","journal-title":"J. Inorg. Biochem."},{"key":"B134","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"B135","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/j3nc79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12031-019-01276-1","article-title":"Iron deficiency, cognitive functions, and neurobehavioral disorders in children","volume":"68","author":"Pivina","year":"2019","journal-title":"J. Mol. Neurosci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2450\/2012.0008-12","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali","year":"2012","journal-title":"Blood Transfus."},{"key":"B139","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jsb.2005.11.001","article-title":"Study of the localization of iron, ferritin, and hemosiderin in Alzheimer\u2019s disease hippocampus by analytical microscopy at the subcellular level","volume":"153","author":"Quintana","year":"2006","journal-title":"J. Struct. Biol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.5c00297","article-title":"Challenges and opportunities for incorporating physiological information into pharmacokinetic models of intranasal drug delivery to the brain: a review of the current status and future trajectories","volume":"22","author":"Rezaee","year":"2025","journal-title":"Mol. Pharm."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal formulations: promising strategy to deliver vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"B143","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.4081\/ni.2017.7279","article-title":"A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients","volume":"9","author":"Rohani","year":"2017","journal-title":"Neurol. Int."},{"key":"B144","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.spen.2006.08.002","article-title":"Brain Iron metabolism","volume":"13","author":"Rouault","year":"2006","journal-title":"Seminars Pediatr. Neurology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.revmed.2023.07.002","article-title":"Diagnosis and treatment of iron overload","volume":"44","author":"Ruivard","year":"2023","journal-title":"Rev. Med. Interne"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e0221978","DOI":"10.1371\/journal.pone.0221978","article-title":"Distraction of olfactory bulb-medial prefrontal cortex circuit may induce anxiety-like behavior in allergic rhinitis","volume":"14","author":"Salimi","year":"2019","journal-title":"PLoS One"},{"key":"B148","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/medethics-2019-105498","article-title":"Institutional conflict of interest: attempting to crack the deferiprone mystery","volume":"47","author":"Schafer","year":"2021","journal-title":"J. Med. Ethics"},{"key":"B149","doi-asserted-by":"publisher","first-page":"720658","DOI":"10.4061\/2011\/720658","article-title":"Iron and mechanisms of neurotoxicity","volume":"2011","author":"Salvador","year":"2010","journal-title":"Int. J. Alzheimers Dis."},{"key":"B150","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archotol.134.6.643","article-title":"Intranasal administration of drugs","volume":"134","author":"Scheibe","year":"2008","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1161\/STROKEAHA.111.617589","article-title":"Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage","volume":"42","author":"Selim","year":"2011","journal-title":"Stroke"},{"key":"B152","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S1474-4422(19)30069-9","article-title":"Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial","volume":"18","author":"Selim","year":"2019","journal-title":"Lancet Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neuropharm.2003.09.005","article-title":"Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats","volume":"46","author":"Shachar","year":"2004","journal-title":"Neuropharmacology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"124","DOI":"10.13004\/kjnt.2025.21.e9","article-title":"Deferoxamine for spontaneous intracranial hemorrhage: a pilot study on neurological and radiological outcomes","volume":"21","author":"Shirani","year":"2025","journal-title":"Korean J. Neurotrauma"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2214-109X(13)70001-9","article-title":"Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data","volume":"1","author":"Stevens","year":"2013","journal-title":"Lancet Glob. Health"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1152\/physrev.00027.2007","article-title":"Diffusion in brain extracellular space","volume":"88","author":"Sykova","year":"2008","journal-title":"Physiol. Rev."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/acs.molpharmaceut.2c00943","article-title":"Topical administration of verapamil in poly(ethylene glycol)-modified liposomes for enhanced sinonasal tissue residence in chronic rhinosinusitis: ex vivo and in vivo evaluations","volume":"20","author":"Taha","year":"2023","journal-title":"Mol. Pharm."},{"key":"B158","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B159","unstructured":"Nasal drug delivery technology global market report 2025\n          \n          \n          2025"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/13872877241313031","article-title":"Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins","volume":"103","author":"Thorwald","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"B161","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3111\/13696998.2010.516203","article-title":"Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients","volume":"13","author":"Tolley","year":"2010","journal-title":"J. Med. Econ."},{"key":"B171","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.annemergmed.2016.08.450","article-title":"Optimal volume of administration of intranasal midazolam in children: a randomized clinical trial","volume":"69","author":"Tsze","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s13311-022-01257-0","article-title":"Novel antidepressant-like properties of the iron chelator deferiprone in a mouse model of depression","volume":"19","author":"Uzungil","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B166","doi-asserted-by":"publisher","first-page":"112","DOI":"10.9734\/jpri\/2021\/v33i34b31853","article-title":"Brain targeting through intranasal route: an overview","author":"Vidyavathi","year":"2021","journal-title":"J. Pharm. Res. Int."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e0011607","DOI":"10.1371\/journal.pntd.0011607","article-title":"Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by deferiprone","volume":"17","author":"Wang","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B168","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13148-023-01575-w","article-title":"Effects of iron homeostasis on epigenetic age acceleration: a two-sample Mendelian randomization study","volume":"15","author":"Wang","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"B169","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.3390\/ijms23137267","article-title":"Iron, neuroinflammation and neurodegeneration","volume":"23","author":"Ward","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2019.2309","article-title":"Association of prenatal maternal anemia with neurodevelopmental disorders","volume":"76","author":"Wiegersma","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/antiox12111997","article-title":"Brain iron homeostasis and mental disorders","volume":"12","author":"Wu","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B173","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2024.01.053","article-title":"Advances and future perspectives of intranasal drug delivery: a scientometric review","volume":"367","author":"Xu","year":"2024","journal-title":"J. Control Release"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1021\/mp5008376","article-title":"Comparative biodistribution and pharmacokinetic analysis of Cyclosporine-A in the brain upon intranasal or intravenous administration in an oil-in-water nanoemulsion formulation","volume":"12","author":"Yadav","year":"2015","journal-title":"Mol. Pharm."},{"key":"B175","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.nano.2015.12.374","article-title":"Intranasal brain delivery of cationic nanoemulsion-encapsulated TNF\u03b1 siRNA in prevention of experimental neuroinflammation","volume":"12","author":"Yadav","year":"2016","journal-title":"Nanomedicine"},{"key":"B176","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1124\/jpet.118.254672","article-title":"CNS delivery and anti-inflammatory effects of intranasally administered Cyclosporine-A in cationic nanoformulations","volume":"370","author":"Yadav","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B177","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jpeds.2020.09.039","article-title":"Association of anemia with neurodevelopmental disorders in a nationally representative sample of US children","volume":"228","author":"Yang","year":"2021","journal-title":"J. Pediatr."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1096\/fj.201801116RR","article-title":"Brain iron loading impairs DNA methylation and alters GABAergic function in mice","volume":"33","author":"Ye","year":"2019","journal-title":"FASEB J."},{"key":"B179","doi-asserted-by":"publisher","first-page":"e0122371","DOI":"10.1371\/journal.pone.0122371","article-title":"The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1089\/neu.2017.5033","article-title":"Effects of deferoxamine mesylate on hematoma and perihematoma edema after traumatic intracerebral hemorrhage","volume":"34","author":"Yu","year":"2017","journal-title":"J. Neurotrauma"},{"key":"B181","doi-asserted-by":"publisher","first-page":"154","DOI":"10.12688\/f1000research.128810.2","article-title":"Comparison of oral iron chelators in the management of transfusion-dependent beta-thalassemia major based on serum ferritin and liver enzymes","volume":"12","author":"Yusuf","year":"2023","journal-title":"F1000Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/mds.20550","article-title":"In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage","volume":"20","author":"Zecca","year":"2005","journal-title":"Mov. Disord."},{"key":"B183","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12974-023-02875-x","article-title":"Nrf2 regulates iron-dependent hippocampal synapses and functional connectivity damage in depression","volume":"20","author":"Zeng","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1007\/s12035-020-02277-7","article-title":"New insights into the role of ferritin in iron homeostasis and neurodegenerative diseases","volume":"58","author":"Zhang","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"111341","DOI":"10.1016\/j.cbi.2024.111341","article-title":"Deferoxamine-induced neurotoxicity: role of chaperone-mediated autophagy dysfunction in neuronal apoptosis in the hippocampus","volume":"406","author":"Zhang","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/nar\/gkt1090","article-title":"Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and tet-dependent mechanism","volume":"42","author":"Zhao","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B187","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2011.10.006","article-title":"Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases","volume":"133","author":"Zheng","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/15376516.2022.2053254","article-title":"Deferoxamine ameliorated Al(mal)(3)-induced neuronal ferroptosis in adult rats by chelating brain iron to attenuate oxidative damage","volume":"32","author":"Zhu","year":"2022","journal-title":"Toxicol. Mech. Methods"},{"key":"B189","doi-asserted-by":"publisher","first-page":"673600","DOI":"10.3389\/fnins.2021.673600","article-title":"Inborn errors of metabolism associated with autism spectrum disorders: approaches to intervention","volume":"15","author":"Zigman","year":"2021","journal-title":"Front. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1709259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:44:51Z","timestamp":1766040291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1709259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":171,"alternative-id":["10.3389\/fphar.2025.1709259"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1709259","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1709259"}}